Iovance Biotherapeutics (IOVA)
(Real Time Quote from BATS)
$8.17 USD
-0.26 (-3.08%)
Updated Jun 14, 2024 10:52 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Iovance Biotherapeutics, Inc. [IOVA]
Reports for Purchase
Showing records 41 - 60 ( 183 total )
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Lifileucil''s BLA Accepted by the FDA; PDUFA Date November 23, 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Lifileucel Gears Up For Potential Commercial Launch During BLA Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Lifileucel Checks a Significant Regulatory Box; BLA Submission Completed
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2022 Results; Launch Preparation in Full Swing as BLA Completion Approaches
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Proleukin Acquisition a Smart Addition to an Active Portfolio of TIL Therapies - Rating: Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Patience Is a Virtue; Lifileucel''s Rolling BLA Completion Now Expected in 1Q23; PT to $38
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
C-144-01 Dives Into the Deep End with New Pooled Analysis at SITC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; C-144-01 Update at SITC; Lifileucel BLA Completion on Schedule for 4Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IOV-4001 Takes First Step in the Clinic; Finalization of Lifileucel BLA Submission Imminent
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Lifileucel Approaches Finish Line With the Initiation of a Rolling BLA; Long Time Coming
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J